Published in Hepatology on December 19, 2011
Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest (2013) 1.64
Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer (2012) 1.32
Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma. Oncotarget (2015) 1.22
Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 1.18
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol (2012) 1.10
Defining the extracellular matrix using proteomics. Int J Exp Pathol (2013) 1.03
Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer (2015) 1.01
Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int (2012) 0.99
Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver (2013) 0.98
Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma. PLoS One (2012) 0.96
A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol (2016) 0.94
Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol (2016) 0.94
The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev (2014) 0.91
The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol (2013) 0.89
Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer (2014) 0.89
Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells. Oncogenesis (2012) 0.88
Glycosylation and liver cancer. Adv Cancer Res (2015) 0.88
Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep (2015) 0.87
Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma. Mol Cancer (2014) 0.86
Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.86
Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget (2016) 0.85
Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85
Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med (2015) 0.84
Schistosome-induced cholangiocyte proliferation and osteopontin secretion correlate with fibrosis and portal hypertension in human and murine schistosomiasis mansoni. Clin Sci (Lond) (2015) 0.84
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Elevated serum osteopontin levels in chronic hepatitis C virus infection: association with autoimmune rheumatologic manifestations. J Clin Immunol (2012) 0.82
Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations. PLoS One (2013) 0.82
The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis. Sci Rep (2015) 0.81
Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer. Cancer Cell Int (2014) 0.81
Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma. Hepat Mon (2015) 0.81
Two-Dimensional N-Glycan Distribution Mapping of Hepatocellular Carcinoma Tissues by MALDI-Imaging Mass Spectrometry. Biomolecules (2015) 0.80
Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg Nutr (2014) 0.80
Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. Clin Sci (Lond) (2014) 0.80
miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Res (2015) 0.80
Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One (2016) 0.80
Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One (2016) 0.79
RAN GTPase and Osteopontin in Pancreatic Cancer. Pancreat Disord Ther (2013) 0.79
Plasma osteopontin in acute liver failure. Cytokine (2015) 0.79
The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. Cell Death Differ (2015) 0.79
Role of hepatitis C virus induced osteopontin in epithelial to mesenchymal transition, migration and invasion of hepatocytes. PLoS One (2014) 0.78
Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World J Hepatol (2015) 0.78
Defective Initiation of Liver Regeneration in Osteopontin-Deficient Mice after Partial Hepatectomy due to Insufficient Activation of IL-6/Stat3 Pathway. Int J Biol Sci (2015) 0.78
CISD2 associated with proliferation indicates negative prognosis in patients with hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.78
The inhibitory effects of extracellular ATP on the growth of nasopharyngeal carcinoma cells via P2Y2 receptor and osteopontin. J Exp Clin Cancer Res (2014) 0.78
Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening. BMC Gastroenterol (2015) 0.78
Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep (2015) 0.78
Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prev Res (Phila) (2016) 0.77
Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children. Mem Inst Oswaldo Cruz (2013) 0.76
SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep (2016) 0.76
Role of Osteopontin in Liver Diseases. Int J Biol Sci (2016) 0.76
Targeting late SV40 factor: is the achilles heel of hepatocarcinogenesis revealed? World J Gastroenterol (2012) 0.76
Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. J Immunother Cancer (2016) 0.75
Disease monitoring of hepatocellular carcinoma through metabolomics. World J Hepatol (2017) 0.75
High expression of GNA13 is associated with poor prognosis in hepatocellular carcinoma. Sci Rep (2016) 0.75
Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep (2017) 0.75
Identification of novel amelogenin-binding proteins by proteomics analysis. PLoS One (2013) 0.75
Association of osteopontin polymorphism with cancer risk: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Proteomic approaches to analyzing hepatitis C virus biology. Proteomics (2015) 0.75
Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Lett (2017) 0.75
The role of serum biomarkers in hepatocellular carcinoma surveillance. Gastroenterol Hepatol (N Y) (2011) 0.75
Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. World J Gastroenterol (2016) 0.75
Biomarkers for Hepatocellular Carcinoma. Biomark Cancer (2017) 0.75
Human Endogenous Retroviruses-K (HML-2) Expression Is Correlated with Prognosis and Progress of Hepatocellular Carcinoma. Biomed Res Int (2016) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
Up-regulation of brain-expressed X-linked 2 is critical for hepatitis B virus X protein-induced hepatocellular carcinoma development. Oncotarget (2017) 0.75
Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediators Inflamm (2017) 0.75
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist (2010) 4.68
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Epidemiology of hepatocellular carcinoma in USA. Hepatol Res (2007) 2.56
Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology (2004) 2.08
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist (2010) 1.84
Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer (2003) 1.74
Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology (2008) 1.61
Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med (2010) 1.53
Non-alcoholic steatohepatitis and cancer. Clin Liver Dis (2007) 1.44
Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol (2010) 1.40
Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci (2008) 1.29
Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology (2008) 1.27
Osteopontin as a target for cancer therapy. Front Biosci (2008) 1.21
Serum markers of hepatocellular carcinoma. Semin Liver Dis (2006) 1.17
The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol (2006) 1.14
Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis (2006) 1.08
Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology (2004) 1.07
Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand. Hepat Res Treat (2011) 0.88
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res (2002) 7.11
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst (2008) 6.79
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res (2006) 4.00
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol (2009) 3.90
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Evaluating the predictiveness of a continuous marker. Biometrics (2007) 3.54
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 3.15
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem (2002) 3.05
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res (2007) 2.88
Lung cancer risk among female textile workers exposed to endotoxin. J Natl Cancer Inst (2007) 2.87
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics (2003) 2.69
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One (2011) 2.48
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett (2006) 2.37
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
The human proteome project: current state and future direction. Mol Cell Proteomics (2011) 2.34
DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene (2002) 2.27
Occupational risk factors for esophageal and stomach cancers among female textile workers in Shanghai, China. Am J Epidemiol (2006) 2.27
Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem (2004) 2.26
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 2.26
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res (2005) 2.24
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Genetics of lung-cancer susceptibility. Lancet Oncol (2010) 2.24
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Presence of simian virus 40 DNA sequences in human lymphomas. Lancet (2002) 2.21
MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology (2008) 2.19
Air pollution and risk of lung cancer in a prospective study in Europe. Int J Cancer (2006) 2.17
Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis (2007) 2.16
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology (2008) 2.14
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09
Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem (2002) 2.08
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 2.07
Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform (2003) 2.04
Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet (2009) 2.02
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat (2002) 1.99
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl (2007) 1.96
Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med (2005) 1.93
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol (2003) 1.91
On the origin of G --> T transversions in lung cancer. Mutat Res (2003) 1.89
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res (2013) 1.88
Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest (2010) 1.88
Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium. Am J Epidemiol (2015) 1.87
Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol (2011) 1.85
Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res (2009) 1.84
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate (2009) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol (2009) 1.82
Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology (2010) 1.80
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med (2013) 1.79
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology (2006) 1.78
An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers. J Biomed Biotechnol (2003) 1.73
Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran. Gut (2010) 1.71
The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology (2004) 1.69
Biases introduced by choosing controls to match risk factors of cases in biomarker research. Clin Chem (2012) 1.69
Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med (2007) 1.66
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark (2007) 1.65